A Phase 3 interventional study of Semaglutide and Berobenatide in Obesity, Overweight and/or Obesity and Overweight, sponsored by Pfizer. Recruiting at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing berobenatide in Obesity — 11 open to participants now, 15 under way, 12 of them phase 3. berobenatide · Obesity.
Among the 21 studies testing berobenatide in Obesity, this one is the 6th largest by planned enrollment, is one of 15 that started in 2026, is one of 12 in phase 3, reaches primary completion later than 5 of the 14 other live ones, and was the 15th registered.
11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →11 of the 21 studies testing berobenatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 18+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in Japan
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 12
First in 2024; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 660 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 258 across the 21 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 21 have an industry lead sponsor. The 2 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
64 studies in Obesity by Pfizer: 13 open now, 19 under way, 12 of them phase 3. Of 43 finished, 11 (26%) have results posted.
Among the 64 studies in Obesity by Pfizer, this one is the 12th largest by planned enrollment of the 62 interventional ones that give a count, is one of 19 that started in 2026, is one of 16 in phase 3, reaches primary completion later than 8 of the 18 other live ones, and was the 57th registered.
Pfizer’s Obesity studies by the year they started, since 2004.
5 of the studies testing berobenatide in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311850Phase 3PfizerEfficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | 2027-09-21 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07508241PfizerA Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity | 2027-01-27 |
| NCT07845513PfizerA Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity | 2027-02-21 |
| NCT07876531PfizerA Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity | 2027-04-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 21 studies testing berobenatide in Obesity, from their registry updates:
Among Pfizer’s 64 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes.
Participants will be in the study for about 11 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive Semaglutide or Tirzepatide by Subcutaneous Injection.
Drug: Semaglutide · Drug: Tirzepatide
Participants will receive Berobenatide by Subcutaneous Injection.
Drug: Berobenatide
Participants will receive Semaglutide administered subcutaneously.
Participants will receive berobenatide solution for injection as subcutaneous injection.
Also known as: MET097, PF-08653944
Participants will receive Tirzepatide administered subcutaneously.
Percent change from baseline in body weight
Time frame: Baseline, Week 32
Change from baseline in body weight
Time frame: Baseline, Week 32
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: Baseline, Week 32
Number of Participants with Serious adverse events (SAEs)
Time frame: Baseline, Week 32
Number of Participants with adverse events leading to discontinuation
Time frame: Baseline, Week 32
Number of Participants with Adverse Events of Special Interest (AESIs)
Time frame: Baseline, Week 32
Number of Participants with Clinical Laboratory Abnormalities
Time frame: Baseline, Week 32
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Sep 2026 (actual). Primary completion is estimated for Feb 2028, 16 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 16 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Oct 15, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Berobenatide